Home Prostaglandin induced cortical hyperostosis in neonates with cyanotic heart disease
Article
Licensed
Unlicensed Requires Authentication

Prostaglandin induced cortical hyperostosis in neonates with cyanotic heart disease

  • A. M. Nadroo , S. Shringari , M. Garg and A. M. Al-Sowailem
Published/Copyright: June 1, 2005
Journal of Perinatal Medicine
From the journal Volume 28 Issue 6

Abstract

Objective: To study the side effects of prolonged prostaglandin therapy especially hyperostosis and other musculoskeletal changes.

Methods: Case files of the neonates, with cyanotic heart disease, who had received prostaglandin infusion from early days of life, were reviewed. Patients with periosteal changes were identified. Their radiographs, serum alkaline phosphatase activity, duration and dose of prostaglandin and other side effects related to the prostaglandin were studied.

Results: Ten patients developed hyperostosis, who had received PGE1 infusion for a period of 9 to 195 days. Two babies developed coarse facial features, hypertrichosis, and edema of extremities and digital swelling. Serum alkaline phosphatase activity was significantly raised in the patients, with hyperostosis. Besides long bones, ribs and scapulae, the clavicles were also involved. The involvement of clavicles has not been previously reported.

Conclusion: Hyperostosis is a common side effect of prolonged prostaglandin therapy. Abnormal facial features, hypertrichosis and coarse skin are additional adverse effects of long term therapy. Serum alkaline phosphatase activity can be used as a marker of the hyperostosis. In addition to other bones clavicles can also be involved. The above effects seem to be both dose and duration dependent.

:
Published Online: 2005-06-01
Published in Print: 2000-11-20

Copyright (c)2000 by Walter de Gruyter GmbH & Co. KG

Downloaded on 7.10.2025 from https://www.degruyterbrill.com/document/doi/10.1515/JPM.2000.060/html
Scroll to top button